Clinical Trial Update: Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term antibody persistence at 1, 3, and 5 years after a fourth Hib-MenCY-TT dose, compared with ActHIB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Meningococcal Disease

Drugs mentioned

• ACTHIB (Haemophilus influenzae type b conjugate vaccine)
• Hib-MenCY-TT

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED | Results posted: 2012-07-20